Novo Nordisk Liraglutide Filing Planned In Q2 2008 For Diabetes
Final Phase III study in LEAD program shows benefit after one year of monotherapy with the once-daily human GLP-1 analogue.
Final Phase III study in LEAD program shows benefit after one year of monotherapy with the once-daily human GLP-1 analogue.